JP2006518383A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518383A5
JP2006518383A5 JP2006503391A JP2006503391A JP2006518383A5 JP 2006518383 A5 JP2006518383 A5 JP 2006518383A5 JP 2006503391 A JP2006503391 A JP 2006503391A JP 2006503391 A JP2006503391 A JP 2006503391A JP 2006518383 A5 JP2006518383 A5 JP 2006518383A5
Authority
JP
Japan
Prior art keywords
composition
concentration
acetate
composition according
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/003515 external-priority patent/WO2004073608A2/en
Publication of JP2006518383A publication Critical patent/JP2006518383A/ja
Publication of JP2006518383A5 publication Critical patent/JP2006518383A5/ja
Pending legal-status Critical Current

Links

JP2006503391A 2003-02-20 2004-02-05 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 Pending JP2006518383A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20
PCT/US2004/003515 WO2004073608A2 (en) 2003-02-20 2004-02-05 Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006326249A Division JP2007056041A (ja) 2003-02-20 2006-12-01 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物

Publications (2)

Publication Number Publication Date
JP2006518383A JP2006518383A (ja) 2006-08-10
JP2006518383A5 true JP2006518383A5 (https=) 2007-02-01

Family

ID=32908675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006503391A Pending JP2006518383A (ja) 2003-02-20 2004-02-05 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物
JP2006326249A Withdrawn JP2007056041A (ja) 2003-02-20 2006-12-01 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006326249A Withdrawn JP2007056041A (ja) 2003-02-20 2006-12-01 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物

Country Status (16)

Country Link
US (2) US20060074061A1 (https=)
EP (1) EP1594511A2 (https=)
JP (2) JP2006518383A (https=)
KR (1) KR20050102653A (https=)
CN (1) CN100431544C (https=)
AR (1) AR043252A1 (https=)
AU (1) AU2004212900A1 (https=)
BR (1) BRPI0407742A (https=)
CA (1) CA2516790A1 (https=)
MX (1) MXPA05008396A (https=)
PL (1) PL378209A1 (https=)
RU (1) RU2005129278A (https=)
TW (1) TW200507858A (https=)
UY (1) UY28203A1 (https=)
WO (1) WO2004073608A2 (https=)
ZA (1) ZA200505990B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
KR20080059175A (ko) * 2005-09-07 2008-06-26 사우스웨스트 리서치 인스티튜트 방출속도가 향상된 생분해성 미립자 약제학적 제제
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
CN101346473A (zh) * 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
JP2010534201A (ja) * 2007-07-20 2010-11-04 アルコン,インコーポレイテッド 受容体チロシンキナーゼ阻害(RTKi)化合物の目への送達のための医薬製剤
EP2977084B1 (en) * 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US20170106047A1 (en) * 2014-06-12 2017-04-20 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
PT1221918E (pt) * 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Similar Documents

Publication Publication Date Title
JP2006518383A5 (https=)
JP2020502197A5 (https=)
JP2008535850A5 (https=)
WO2006012227A3 (en) Amido compounds and their use as pharmaceuticals
JP2011516521A5 (https=)
JP2008044951A5 (https=)
JP2010222367A5 (https=)
WO2006020598A3 (en) Amido compounds and their use as pharmaceuticals
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
JP2010132695A5 (https=)
RU2008118889A (ru) Спососб лечения первичных и вторичных форм глаукомы
MX340538B (es) Compuestos amido y sus usos como farmaceuticos.
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
JP2009506071A5 (https=)
HRP20160646T1 (hr) Poboljšano liječenje multiplog mijeloma
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
WO2006012226A3 (en) N-substituted piperidines and their use as pharmaceuticals
WO2006055752A3 (en) INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
DK1453487T3 (da) Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud
EP1807146A4 (en) COMPOSITION TO IMPROVE THE EFFICIENCY OF THE MEDICINAL PRODUCT
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
DE602005021909D1 (de) Transdermale verabreichungssysteme
TW200815410A (en) Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
ATE277620T1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat